MILabs takes home WMIS innovation award
Frederik Beekman, CEO and CSO of MILabs, won the World Molecular Imaging Society (WMIS) Commercial Innovation of the Year Award at this month’s World Molecular Imaging Congress (WMIC) in Honolulu.
Beekman was presented with the award, which is voted on by WMIS attendees, for his work over the last nine years on G-SPECT. G-SPECT is a clinical SPECT platform that features a resolution of less than 3 mm and lowered imaging doses.
"It is great that so many in the molecular imaging community, both academic and commercial, voted for the G-SPECT, and that they seem to feel that we are at the start of something that may become a game-changer," Beekman said in a statement. "MILabs employees are very proud and pleased that the results of their work is appreciated and recognized by the molecular imaging community."
H. Charles Manning, PhD, a program chair for WMIC 2015, said it was “extremely rewarding” that WMIS attendees voted on the award winner.
"The voice of the WMIS is composed of the 'best and the brightest' in molecular imaging from around the globe; thus, it means a lot that every attendee-member had an equal share in selecting the most innovative technology presented this year,” Manning said in a statement.
This was the first WMIS Commercial Innovation of the Year Award, and it will now be presented annually.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.